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Abstract
Background: Circular RNAs are non-coding RNA molecules with gene regulatory potential that have been
associated with several human diseases. They are stable and present in the circulation, making them excellent
candidates for biomarkers of disease. Despite their promise as biomarkers or future therapeutic targets, information
on their expression and functionality in human pancreatic islets is a relatively unexplored subject.
Methods: Here we aimed to produce an enriched circRNAome profile for human pancreatic islets by CircleSeq, and
to explore the relationship between circRNA expression, diabetes status, genotype at T2D risk loci and measures of
glycaemia (insulin secretory index; SI and HbA1c) in human islet preparations from healthy control donors and
donors with type 2 diabetes using ANOVA or linear regression as appropriate. We also assessed the effect of
elevated glucose, cytokine and lipid and hypoxia on circRNA expression in the human beta cell line EndoC-βH1.
Results: We identified over 2600 circRNAs present in human islets. Of the five most abundant circRNAs in human
islets, four (circCIRBP, circZKSCAN, circRPH3AL and circCAMSAP1) demonstrated marked associations with diabetes
status. CircCIRBP demonstrated an association with insulin secretory index in isolated human islets and circCIRBP and
circRPH3AL displayed altered expression with elevated fatty acid in treated EndoC-βH1 cells. CircCAMSAP1 was also
noted to be associated with T2D status in human peripheral blood. No associations between circRNA expression
and genotype at T2D risk loci were identified in our samples.
Conclusions: Our data suggest that circRNAs are abundantly expressed in human islets, and that some are
differentially regulated in the islets of donors with type 2 diabetes. Some islet circRNAs are also expressed in
peripheral blood and the expression of one, circCAMSAP1, correlates with diabetes status. These findings highlight
the potential of circRNAs as biomarkers for T2D.
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Background
One of the key difficulties in dissecting the factors driv-
ing progression of multifactorial polygenic chronic dis-
eases such as type 2 diabetes (T2D) is the degree of
heterogeneity that it presents. Although the development
of diabetes like other common chronic disorders has a
large lifestyle contribution, there is a substantial genetic
component [1]. 70% of individuals with prediabetes
eventually develop diabetes [2, 3], with increasing evi-
dence suggesting that diabetic complications such as
peripheral nephropathy and retinopathy may initiate at
the pre-diabetic stage [2]. Identifying people at risk of
type 2 diabetes, or those likely to progress from impaired
glucose tolerance to overt disease is thus an important
aim. Understanding the molecular causes of T2D, and
identification of sensitive and specific biomarkers to in-
dicate those at risk of pre-diabetes, or of transition from
pre-diabetes to overt disease is therefore a key aim for
research.
Genome wide association studies (GWAS) for T2D have
identified over 143 risk loci associated with susceptibility
to T2D [1]. More than 85% of these disease-associated
variants reside in non-coding regions of the genome [4].
Over 80% of the human genome is predicted to display
some degree of functionality [5], so it is likely that many
of the diabetes-associated genetic variants may act via dys-
regulation of gene expression. Disruption of the activity or
function of non-coding RNAs that moderate gene activity,
such as microRNA (miRNA) or long non-coding RNA
(lncRNA) may have particular relevance [6].
Circular RNAs (circRNAs) are an emerging class of
non-coding RNA (ncRNA) generated by the back spli-
cing of downstream exons to the 3′ acceptor splice site
of upstream exons and result in a covalently closed cir-
cular structure containing one or more exons [7]. Their
mode(s) of action remain to be fully elucidated but they
have been suggested to manipulate gene expression by
moderation of transcription [8], interaction with cellular
proteins [9], sequestration of RNA-binding proteins [10]
or sponging miRNA [11]. Their covalently closed struc-
ture means that they are resistant to exonucleases; ac-
cordingly, they have half-lives on average 19–24 h [12],
being significantly more stable than linear mRNAs from
their cognate genes which have half-lives typically in the
region of 4–9 h [13]. Data on circRNA abundance can
be extracted from conventional NGS data, but such data
may also include aberrant back spliced sequences from
linear transcripts as well as genuine circRNAs.
CircRNAs may have potential as biomarkers for the
development of diabetes or as future molecular targets
for novel diabetes therapeutics [14–16]. An important
pre-requisite for this is the characterisation of circRNA
sequences in diabetes-relevant tissues such as pancreatic
islets and in more accessible tissues such as peripheral
blood. Cell-type specific circRNA expression has previ-
ously been reported in human pancreatic α, β and δ cells
[17], but these profiles were not circRNA-specific, being
extracted from published NGS data in the absence of
RNase R treatment to remove linear RNA. Other human
islet circRNA profiles have been generated using micro-
array approaches, which will capture only known cir-
cRNAs [18].
We present here an enriched whole circRNAome pro-
file from primary human pancreatic islets which we have
generated using a modified circleSeq technique [19].
This included an RNase R step to remove linear RNA
and enrich for circRNAs. We firstly aimed to determine
whether expression of the most abundantly-expressed
islet circRNAs were associated with insulin secretory
index (SI), donor HbA1c or donor diabetes status in hu-
man primary islets. Secondly, we aimed to determine
whether circRNAs localising to the genomic regions
encompassing the GWAS association signals for type 2
diabetes were differentially-expressed according to donor
risk genotype. Thirdly, we aimed to explore whether
abundantly-expressed circRNAs were responsive to dia-
betomimetic stimuli (hypo- or hyperglycaemia, hypoxia,
elevated fatty acids or inflammatory cytokines), in the
human beta cell line EndoC-βH1. Finally, we aimed to
determine whether abundant islet circRNAs were differ-
entially expressed in the peripheral blood of individuals
with pre-diabetes or overt disease.
We identified 2619 circRNAs that were expressed in
islet donors, 47 of which had not been previously identi-
fied in data from human tissues. 4/5 of the most abun-
dant circRNA demonstrated differential expression in
the islets of donors with T2D, whilst 2/5 demonstrated
dysregulated expression in response to elements of the
diabetic microenvironment in the human beta cell line
EndoC-βH1 in culture. No circRNA co-localising to the
GWAS signals for T2D demonstrated associations with
risk genotype. Finally, 3/5 of the most abundant islet cir-
cRNAs were also expressed in blood, and the expression
of one, circCAMSAP1, demonstrated an association with
T2D status in the peripheral blood of patients with T2D,
but not with impaired glucose tolerance (IGT). To con-
clude, we have produced the first global circRNA-only
profile in human pancreatic islets, provided evidence
that some are differentially expressed in the islets of do-
nors with diabetes. One islet circRNA (circCAMSAP1) is
also differentially expressed in the peripheral blood of
subjects with T2D, highlighting a potential use for cir-
cRNA species as biomarkers of disease.
Methods
Pancreatic islet preparations
Snap-frozen islet preparations were purchased from Pro-
Cell Biotech (Newport Beach, CA, USA) or from the
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Table 1 Sample and donor characteristics for human islet samples used in this work
A.
Control (n = 50) T2D (n = 20) p-value
Mean SD Mean SD
Age 40.66 14.25 53.55 9.22 < 0.001
BMI 28.30 6.83 33.05 10.31 0.027
SI 2.45 1.26 – – –
HbA1c 5.44 0.36 – – –
Purity 89.28 6.00 80.38 14.92 < 0.001
Viability 93.53 4.80 89.73 4.54 0.003
Sex F (40%); M (60%) F (45%) M (55%) 0.706
Ethnicity white (74%) other (26%) white (45%) other (55%) 0.348
B.
Major allele homozygotes Heterozygotes and minor allele homozygotes p-value
Mean SD Mean SD
rs6819243 (CTBP1)
Age 40.19 14.12 42.38 11.78 0.620
BMI 27.85 5.34 27.16 7.03 0.715
Purity 89.26 5.86 90.00 3.54 0.671
Viability 93.33 5.68 94.12 2.38 0.633
Sex F (53%) M (47%) F (38%) M (62%) 0.595
Ethnicity white (83%) other (17%) white (31%) other (69%) 0.020
rs10758593 (GLIS3)
Age 41.08 15.04 40.88 12.25 0.966
BMI 26.27 4.14 29.07 5.80 0.130
Purity 89.46 4.96 88.50 6.26 0.633
Viability 94.81 3.09 92.33 5.37 0.133
Sex F (39%) M (62%) F (42%) M (58%) 0.269
Ethnicity white (69%) other (31%) white (73%) other (27%) 0.916
rs7177055 (HMG20A)
Age 39.97 13.95 43.69 12.35 0.371
BMI 27.83 5.63 29.87 9.46 0.355
Purity 89.13 5.18 89.13 6.18 0.998
Viability 93.37 4.03 93.34 6.70 0.986
Sex F (47%) M (53%) F (38%) M (63%) 0.547
Ethnicity white (72%) other (28%) white (75%) other (25%) 0.697
rs1111875 (IDE)
Age 48.58 9.95 33.43 12.20 < 0.001
BMI 30.05 8.52 26.50 4.80 0.088
Purity 88.61 4.91 90.57 4.73 0.175
Viability 94.57 3.30 93.57 4.20 0.374
Sex F (58%) M (42%) F (30%) M (70%) 0.056
Ethnicity white (67%) other (33%) white (74%) other (26%) 0.733
rs12427353 (SPPL3)
Age 39.68 14.15 46.80 9.02 0.137
BMI 29.03 7.32 25.03 4.00 0.104
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NIA IIDP resource (collected with ethical permission at
source). Islet purity and viability was determined by di-
thizone and fluorescein diacetate/propidium iodide
staining. Samples were shipped in RNAlater-ICE (Life
Technologies, Carlsbad, CA, USA) to maintain transcript
stability, and RNA was extracted using the total RNA
extraction protocol of the miRVana miRNA isolation kit,
as per the manufacturers’ instructions. Sample RNA In-
tegrity Number (RIN) was determined using an Agilent
Bioanalyser (Agilent, Santa Clara, USA). Fifty three islet
samples were available from healthy donors, and 20 from
donors with T2D. Islet donor characteristics are given in
Table 1, with expanded information on each donor in
Supplementary Table S1.
Generation of human primary islet circRNA profile
For our initial description of the islet circRNome, we gener-
ated circular RNA profiles from a pooled sample consisting
of 5 individual islet preparations from donors without T2D
using a modified ‘CircleSeq’ procedure [20] as in our previ-
ous work [21]. Samples were derived from 3 females and 2
males, with an average age of 50.2 years and an average
BMI of 26.4, and were pooled to prevent any bias arising
from signals arising from single donors. Islet preparations
had, an average viability 94.4% and an average purity of
81%. CircRNA sequencing was carried out as previously
published [21]. Sixty-twoM reads were obtained from the
RNase R-treated sample and 41M reads from the mock-
treated sample. The mean Q score was 38.9–39.1 and the
total error rate was 0.24%. CircRNA sequences were then
determined and quantified as in our previous work [21].
Pathway analysis of genes hosting differentially-regulated
circRNA
To determine whether circRNAs identified were derived
from genes clustered into specific gene ontology
pathways, we carried out an initial gene set enrichment
GSE analysis using the ClueGO Cytoscape version 2.5.2
plug-in (Bindea et al., 2009), as described in our previous
work [21].
Selection of circRNA for validation
CircRNA were selected for follow up on two criteria.
Firstly, levels of individual circRNA in the islet were
ranked by abundance. We selected the 5 circRNAs most
abundantly expressed in islets (circCAMSAP1, cir-
cCIRBP, circRHOBTB3, circRPH3AL and circZKSCAN1)
for further analysis. We also assessed the expression of
the linear reference transcript for each circRNA in each
case. The second class of circRNAs selected for follow
up were those mapping to the GWAS loci for T2D.
The circRNA profile in our study was mapped against
the T2D susceptibility loci [22]. The co-ordinates of the
upstream and downstream exons predicted to constitute
each circRNA were then cross-referenced against the
T2D GWAS signals using a custom Python 2.7 script to
determine whether any circRNAs co-localized within the
recombination windows. Thirteen circRNAs fulfilled
these criteria and were selected for follow up
(circCTBP1_1, circCTBP1_2, circGLIS3, circHMG20A,
circIDE1, circIDE2, circSPPL3_1, circSPPL3_2, cir-
cTHADA1, circTHADA2, circTHADA3, circTHADA4
and circTHADA5). The expression of both circRNA and
their host linear transcripts were assessed.
Design of RT-qPCR assays for circRNA validation
We designed and validated custom quantitative RT-
qPCR assays specific to the unique back-spliced junc-
tions of each circRNA to be followed up. Assay se-
quences are given in Supplementary Table S2. Probes
and primers were placed to avoid genetic variation.
Assay efficiency, linear range and accuracy were
Table 1 Sample and donor characteristics for human islet samples used in this work (Continued)
Purity 89.98 5.22 87.78 5.65 0.267
Viability 93.48 5.28 94.33 3.50 0.645
Sex F (40%) M (60%) F (70%) M (30%) 0.092
Ethnicity white (68%) other (33%) white (80%) other (20%) 0.949
rs10203174 (THADA)
Age 42.18 13.62 43.36 13.38 0.802
BMI 29.07 7.54 25.54 5.13 0.155
Purity 89.64 4.50 89.09 6.25 0.754
Viability 93.85 4.25 94.64 2.46 0.565
Sex F (47%) M (53%) F (36%) M (64%) 0.546
Ethnicity white (74%) other (26%) white (55%) other (45%) 0.920
A. Characteristics of human islet preparations from donors with (n = 20) and without (n = 50) T2D. B. Characteristics of human islet preparations from control
donors used for GWAS genotype analysis (n = 53). SD = standard deviation. Islet sets for parts A and B are only partly overlapping; non-diabetic samples used for
assessment of effects of diabetes status were selected from the larger pool to allow for matching of islet donors with and without diabetes. Differences in
parameters between islet groups was determined by t-test. B. Characteristics of human peripheral blood donors with (n = 20) and without (n = 50) T2D
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determined by 1:10 serial dilutions of synthetics oligonu-
cleotides corresponding to each back spliced junction
(ThermoFisher, Foster City, USA).
Reverse transcription
cDNA synthesis for analysis of circRNA expression in is-
lets, EndoC-βH1 cells and across a panel of tissues was
carried out using the Superscript® VILO™ cDNA synthe-
sis kit (ThermoFisher, Foster City, USA) according to
manufacturer’s instructions. Reactions contained 100 ng/
μL RNA in a final reaction volume of 20 μL. Reaction
conditions were 25 °C for 10 min, 42 °C for 60 min and
85 °C for 5 min.
Expression of islet circRNAs in other tissues
The expression of the 13 circRNAs co-localizing to
T2D-GWAS loci and the 5 most abundant circRNAs
expressed in pancreatic islets and their parent linear
transcripts were assessed in 39 different tissues by quan-
titative RT-qPCR. The tissue panel was commercially-
sourced panel consisting of pooled samples from differ-
ent donors (tissue RNA samples were sourced from
Ambion (Bath, UK), Biochain (Newark, USA) or BD Bio-
sciences (Swindon, UK). Reaction mixes contained
2.5 μL Taqman® Universal PCR mastermix II, no AmpEr-
ase® UNG, (ThermoFisher, Foster City, USA), 1.75 μL
dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene expres-
sion assay (ThermoFisher, Foster City, USA) in a 5 μL
final reaction volume. Cycling conditions were 50 °C for
2 min, 95 °C for 10 min and 50 cycles of 15 s at 95 °C for
30 s and 1min at 60 °C. Reactions were carried out on
the 12 K Flex platform (ThermoFisher, Foster City, USA)
in 3 technical replicates. Target abundance was assessed
using the Comparative Ct method, and was expressed
relative to the geometric mean of the target and control
set as a whole, since endogenous controls alone did not
provide a robust baseline. Data for each target within
the tissue panel was then normalised to its median level
of expression across the entire panel.
Assessment of associations between the islet expression
of abundant circRNAs, insulin secretory index (SI), HbA1c
or T2D status
RNA samples and clinical data were available for islet
preparation from 50 non-diabetic donors and from 20
donors with T2D. Islet donor characteristics are given in
Table 1. We assessed the expression of the 5 most abun-
dant circRNAs expressed in pancreatic islets as well as
their host linear transcripts in relation to insulin
secretory index, HbA1c or diabetes status in these sam-
ples by quantitative RT-qPCR. Reaction mix contained
2.5 μL Taqman® Universal PCR mastermix II, no AmpEr-
ase® UNG, (ThermoFisher, Foster City, USA), 1.75 μL
ddH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene
expression assay (ThermoFisher, Foster City, USA) in a
5 μL final reaction volume. Cycling conditions were
50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 s at
95 °C for 30 s and 1min at 60 °C. Reactions were carried
out on the 12 K Flex platform (ThermoFisher, Foster
City, USA) in 3 technical replicates. Target abundance
was assessed using the Comparative Ct method, and
expressed relative to the geometric mean of the assay
set. Levels of target expression in the islets of donors
with T2D were then normalised to the median level of
that transcript in non-diabetic islets controls. For assess-
ment of SI or HbA1c, expression was normalised to the
median level of each circRNA in control samples. Differ-
ential expression by diabetic status, SI or HbA1C was
then assessed by one way ANOVA using StataSE15 (Sta-
taCorp, Texas, USA), with adjustment made for poten-
tial confounders including age, sex, BMI and ethnicity.
Determination of donor genotype at T2D risk SNPs
RNA samples and phenotypic data were available from
53 non-diabetic islet donors. Characteristics of partici-
pants are given in Table 1 and supplementary Table S1.
The expression of 13 circRNAs co-localising to the gen-
omic regions containing the GWAS association loci for
T2D was assessed in relation to genotype. Genotype at
the GWAS association loci for T2D with expression of
circRNAs located in those regions was accessed by virtue
of the small amounts of genomic DNA which are co-
eluted in RNA preparations upon RNA extraction. We
used a whole genome amplification (WGA) approach to
amplify co-eluted DNA for genotyping using the REPLI-
g Mini kit (Qiagen, Paisley, UK). WGA was carried out
using 2.5 μL RNA and was performed according to man-
ufacturer’s instructions. Genotype was then determined
by Sanger Sequencing of PCR amplicons containing the
SNP in question. PCR reaction mixes included 2.4 μL
primer mix containing a 1:1 ratio of forward: reverse
primers (ThermoFisher, Foster City, USA), 4 μL
MegaMix-Royal (Microzone , Brighton, UK) and 1.60 μL
cDNA in a final reaction volume of 8 μL. Reaction con-
dition for PCR were 95 °C for 12 min, 40 cycles for 95 °C
for 30s, annealing for 1 min, 72 °C for 1 min followed by
72 °C for 10 min. In one case, sequence analysis proved
inconclusive. In this case, genotype was determined by
qPCR with TaqMan® Genotyping assay. Reactions con-
tained 2.5 μL TaqMan® Genotyping Master Mix (Ther-
moFisher, Waltham, MA, USA), 0.25 μL Taqman®
genotyping assay (rs6819243) (ThermoFisher, Waltham,
MA, USA), 1.75 μL dH2O and 0.5 μL whole genome
amplified template in a 5 μL final reaction volume. Tar-
get abundance was assessed using the Comparative Ct
method, and expressed relative to the geometric mean of
the target and control set as a whole. The expression of
each target was then normalised to median levels of that
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target across the collection. Expression levels were then
related to genotype of the islet donors by one way
ANOVA using StataSE15 (StataCorp, Texas, USA) with
adjustment for age, sex, BMI and ethnicity.
Assessment of circRNA expression in EndoC-βH1 under
diabetomimetic conditions
The expression levels of the 5 circRNAs chosen on the
basis of islet abundance and their linear transcripts were
also assessed in the human pancreatic beta cell line
EndoC-βH1, following exposure to dysregulated glucose
(2.5 mM and 25mM), hypoxia (1% O2), dyslipidaemia
(0.5 mM palmitic acid) or proinflammatory cytokines
(TNFα (1000 U/ mL, INFγ (750 U/ mL) and IL1β (75 U/
mL) as described in our previous work [23]. Analysis
was from RNA from different time points selected to ex-
clude effects due to compromised cell viability (up to 48
h for glycemia and lipid treatment, up to 36 h for cyto-
kine treatment and up to 24 h for hypoxia exposure).
CircRNA expression was measured using RT-qPCR as
described above on the 12 K Flex platform (Thermo-
Fisher, Foster City, USA). Target abundance was
assessed using the Comparative Ct method, and
expressed relative to the geometric mean of the target
and control set as a whole, since endogenous controls
alone did not provide a robust baseline. Levels of each
target were then normalised to the median level of each
circRNA in untreated cells. Samples were run in 3 bio-
logical replicates and 3 technical replicates. Differential
circRNA expression in treated cells was then assessed by
one way ANOVA using StataSE15 (StataCorp, Texas,
USA).
RNA extraction from peripheral blood samples from
control donors, donors with IGT and those with T2D
We assessed the expression of the 5 most abundant islet
circRNAs in relation to diabetes status in RNA extracted
from 285 peripheral blood samples from the Exeter 10,
000 study (http://www.peninsulacrf.org/node/155). Our
sample set consisted of 133 non-diabetic patients (fasting
glucose < 100.8 mg/dL), 46 individuals with impaired
glucose tolerance (fasting glucose 100.8 to 122.4 mg/dL)
and 106 patients with overt diabetes (fasting glucose >
122.4 mg/dL). Participant characteristics are given in
Table 2. This collection is a cross sectional population
study consisting of samples collected from volunteer in-
dividuals living in the South West of England and re-
cruited since 2010. Whole blood samples were collected
in 2011/2012 using the PAXgene system [24] and ex-
tracted using the PAXgene Blood RNA kit (Qiagen, Pais-
ley, UK). Written informed consent was obtained for all
participants and ethical permission was granted through
the National Institute for Health Research (NIHR) Clin-
ical Facility (REC 09/H0106/75).
Associations between peripheral blood circRNA
expression and fasting glucose, HbA1c or IGT/T2D status
Peripheral blood RNA samples underwent cDNA synthe-
sis using the EvoScript system and Universal cDNA Mas-
ter kit (Roche Life Science, Burgess Hill, UK). Samples
were normalised to 100 ng/ μL RNA prior to reverse tran-
scription. Reactions were executed according to the man-
ufacturer’s instructions, with a small amendment to
extend the final 65 °C incubation to 30min. We then
assessed the expression of circRNAs that associated with
T2D in islets donors by RT-qPCR as described above. Tar-
get abundance was assessed using the Comparative Ct
method, and expressed relative to the geometric mean of
the target and control set as a whole, since endogenous
controls alone did not provide a robust baseline. Levels of
each circRNA were then normalised to median levels in
non-diabetic blood samples. Differential expression by dia-
betic status (no diabetes or IGT, IGT, overt diabetes) was
then assessed by one way ANOVA using StataSE15 (Stata-
Corp, Texas, USA) with adjustment made for potential
confounders age, sex, BMI and ethnicity.
Results
CircRNA profiling in islets
Two thousand six hundred nineteen circRNAs were
expressed in islet donors in the present study




Mean SD Mean SD
Age 0.016 52.45 17.08 59.26 14.31
BMI < 0.001 26.51 4.13 28.93 3.68
HbA1c – 5.61 0.34 – –
Glucose – 4.85 0.40 – –
Sex 0.004 F (60%); M (40%) F (40%) M (60%)
Ethnicity 0.611 white (99%) other (1%) white (100%) other (0%)
B.
p-value Control T2D
Mean SD Mean SD
Age < 0.001 52.45 17.08 68.74 10.65
BMI < 0.001 26.51 4.13 30.61 5.99
HbA1c – 5.61 0.34 – –
Glucose – 4.85 0.40 – –
Sex 0.001 F (60%); M (40%) F (57%) M (43%)
Ethnicity 0.445 white (99%) other (1%) white (99%) other (1%)
A. Anthropometric characteristics of peripheral blood donors with normal
blood glucose (n = 133) and those with impaired glucose tolerance (IGT; n =
46) B. Anthropometric characteristics of peripheral blood donors with normal
blood glucose (n = 133) and those with overt T2D (n = 106). Differences in
parameters between islet groups was determined by t-test
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(Supplementary Table S3). Fourty-seven circRNAs had
not been previously identified in data from multiple hu-
man tissues (multiple brain regions, muscle, thyroid and
liver), and multiple cell types (including stem cells, skin
and lung fibroblasts, neurons, lung epithelia, hepato-
cytes, breast cancer cells, lymphocytes, muscle myo-
blasts, aortic and vascular endothelial cells) analysed
using the circBase and circAtlas databases [25] (http://
zhaolab.biols.ac.cn/). These circRNA are given in Sup-
plementary Table S4. The five circRNAs demonstrating
the highest expression in human islets derived from the
CAMSAP1, CIRBP, RPH3AL, RHOBTB3 and ZKSCAN1
loci. Thirteen circRNAs co-localized with the GWAS as-
sociation signals for T2; these comprised GLIS3 and
HMG20A (1 circRNA each), CTBP1, IDE and SPPL3 (2
circRNAs each) and THADA (five circRNAs). We se-
lected these 18 circRNAs for further follow up. circRNA
structures were predicted based on the sequencing read
depth for each exon and are presented in Fig. 1. Exon
structures presented as read depth plots are given in
Supplementary Figure S1.
Pathway analyses for genes generating islet-specific or
abundant circRNAs
Pathway enrichment analysis was carried out to deter-
mine whether the genes hosting the 47 circRNAs not
identified in other tissues were enriched in any specific
gene ontology (GO) pathways. A similar analysis was
also carried out the genes hosting the top 10% most
abundant circRNAs. Pathways analysis was performed
using ClueGO in Cytoscape (Bindea et al. 2009). The
novel circRNAs demonstrated enrichment for genes in
the ‘pancreatic secretion’ pathway (p = < 0.001). The 10%
most abundantly expressed circRNAs were derived from
genes demonstrating enrichment in the lysine degrad-
ation (p = 0.03), attenuation phase (p = 0.02), RUNX3
(p = 0.02), carcinoma (p = 0.01) and stem cell gene regu-
lation (p < 0.001) pathways (Table 3).
CircRNAs are differentially expressed in a tissue-specific
pattern
We assessed the expression patterns of the 18 circRNAs
selected for further analysis across a panel of human tis-
sues. We demonstrated that the expression patterns of
circRNAs did not always correlate with levels of their
corresponding linear transcripts. The expression levels
of circular and linear forms of the gene were sometimes
divergent, indicating that the circRNAs are regulated in-
dependently from the mRNAs also deriving from the
parental linear gene (Supplementary Figure S2). For in-
stance while circSPPL3_2 was upregulated in most tis-
sues compared to its linear gene, both circCAMSAP1
and circRHOBTB3 roughly followed the pattern of
expression of their linear transcript levels across diver-
gent tissues.
The most abundant islet circRNAs are associated with
insulin secretory index (SI) or T2D status in human islets
4/5 circRNAs that showed marked expression in the is-
lets demonstrated an association with T2D status (Fig. 2,
supplementary Table S5). Three of these circRNAs, cir-
cCAMSAP1, circCIRBP and circRPH3AL satisfied the
multiple testing threshold (p < 0.001). CircZKSCAN1
showed nominal association with T2D status in islet do-
nors (p = 0.030). Of these, the expression of the linear
transcripts of three of these circRNAs, CAMSAP1,
CIRBP and ZKSCAN1 were also significantly associated
with diabetic status (p < 0.001). RHOBTB3 (p < 0.001)
also demonstrated significant association with T2D sta-
tus although its circRNA showed no association. The
majority of these were positive associations, with the ex-
ception of CIRBP and circCIRBP, which were negatively
correlated with T2D status. In addition, circCIRBP dem-
onstrated a nominal negative association with insulin
secretory index (p = 0.028; supplementary Table S5). No
associations were identified between islet circRNA ex-
pression and donor HbA1c.
CircRNA expression is not driven by genotype
We next assessed the expression of circRNAs located in
regions of the genome linked to risk of T2D. Thirteen
circRNAs co-localised with the genomic regions encom-
passing the GWAS association signals for T2D; 2 cir-
cRNAs from the CTBP1 gene (in rs6819243 region), one
circRNA from the GLIS3 gene (rs10758593), one cir-
cRNA from the HMG20A gene (rs7177055), two cir-
cRNAs from the IDE gene (rs1111875), two circRNAs
from the SPPL3 gene (rs12427353) and five circRNAs
deriving from the THADA gene (rs10203174). We iden-
tified no associations between any of these circRNAs
and genotype at these loci (Table 4).
CircRNAs are differentially expressed upon exposure to
stress conditions in EndoC-βH1 cells
Although the 5 most abundant circRNAs expressed in
human islets did not show overt responsiveness to al-
tered glucose, hypoxia or pro-inflammatory cytokines
when tested in the human beta cell line EndoC-βH1,
two (circCIRBP and circRPHAL3) did demonstrate
changes in expression following treatment with 0.5 mM
palmitate. CircCIRBP expression was increased following
treatment (P = 0.021) whereas circRPHAL3 demon-
strated reduced expression (p = 0.022; Table 5). The ex-
pression of the linear transcripts from the RHOBTB3
and ZKSCAN1 genes also demonstrated increased ex-
pression in EndoC-βH1 cells treated with palmitic acid,
in the absence of effects of their respective circRNAs.
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Fig. 1 (See legend on next page.)
Haque et al. BMC Medical Genomics           (2020) 13:64 Page 8 of 15
CircCAMSAP1 is differentially expressed in T2D peripheral
blood
Of the 4 circRNAs demonstrating evidence of altered ex-
pression in the islets of donors with T2D, two (circIDE1
and circRPH3AL) were not expressed in peripheral
blood. Of the three remaining circRNAs with expression
in peripheral blood (circCAMSAP1, circCIRBP and cir-
cZKSCAN1), circCAMSAP1 demonstrated a nominal
negative association with diabetes status in the periph-
eral blood of patients with T2D (Fig. 3; supplementary
Table S6). No difference in expression was detected for
any circRNA between control patients and those with
IGT, or between those with IGT and those with T2D).
No associations were evident between circRNA expres-
sion in peripheral blood and either participant fasting
glucose or HbA1c.
Discussion
We present here the first enriched circRNA profile from
human primary pancreatic islet RNA produced from a
modified NGS CircleSeq protocol with enrichment for
circRNAs. We have identified 2619 circRNAs expressed
in human islets, including 47 circRNAs which were not
identified in profiles from multiple other tissues in cir-
cBase or circAtlas. Some of these novel circRNA are
clustered into pathways representative of pancreatic exo-
crine function, so it is possible that their expression is
pancreatic, rather than islet specific. Of the 18 circRNAs
selected for follow up on the basis of abundance or co-
localisation to the GWAS association signals for T2D,
many also show evidence of regulation independent of
their parent gene. Four out of 5 of the most abundant
circRNAs in human islets demonstrate strong evidence
of dysregulated expression in the islets of human donors
with T2D, with one (circCIRBP) demonstrating an asso-
ciation with insulin secretory index. Two out of 5 also
show dysregulated expression in human EndoC-βH1
beta cells treated with fatty acids although direction of
effect was not conserved. Finally, one circRNA (cir-
cCAMSAP1) also demonstrates an association with dia-
betes status in the peripheral blood of patients with type
2 diabetes.
To date, there have been two circRNA profiles gener-
ated from human pancreatic endocrine cells or intact is-
lets. The first provides a circRNA profile generated from
publically-available NGS data from isolated α, β and δ
cell transcriptomes [17]. This study reported 10,832 pu-
tative circRNAs expressed in total, with 382 shared
across cell types. This study reports more islet circRNAs
than identified in our dataset, but this profile is derived
from conventional NGS data, with no pre-treatment to
remove linear sequences. Back splicing events can be
generated from tandem DNA duplications within genes,
or from trans-splicing events during linear splicing [26],
so it is likely that profiles derived from conventional
NGS contain sequences that in fact represent aberrantly
spliced linear transcripts rather than genuine circRNAs.
Differences will also arise in that this previous circRNA
profile derives from isolated α, β and δ cell populations,
whereas ours is a profile derived from intact islets. Dif-
ferences in gene expression patterns may thus reflect the
effects of cell:cell crosstalk as occurs in vivo. Neverthe-
less, there was considerable overlap between our profile
and the beta cell circRNA profile of Kaur et al. [17]. Of
the top 100 most abundant circRNA in the Kaur profile,
all but 12 had counterparts from the same genes in our
profile. Clustering between the most abundant genes in
the Kaur profile and the most abundant genes in the
(See figure on previous page.)
Fig. 1 Structure of islet circRNAs: CirRNA junction schematics for 13 circular RNAs associated with Type 2 diabetes genome-wide association
studies (a) and the 5 most abundant circRNAs identified in islets (b). Each schematic shows the identified backspliced exon or exons. The relative
read depth at each backspliced junction is shown by the number of bars above each junction and is scaled by linear interpolation, where the
backspliced junctions with 1 and 10 bars represent the junctions with the lowest and highest read depth respectively
Table 3 Pathways enriched in genes generating circRNAs
expressed predominantly in human pancreatic islets
A.









5 CELA3A, CFTR, CPA1,
KCNQ1, PNLIPRP2
B.
Pathways enriched in genes generating the top 10% the most















0.010 6 CREBBP,EP300, FOXO3,
KANSL1, KMT2C, MAML3
Attenuation phase 0.020 3 CREBBP, DNAJB1, EP300
RUNX3 regulates
NOTCH signaling
0.020 3 CREBBP, EP300, MAML3
Lysine degradation 0.030 5 ASHIL, EHMT1, KMT2C,
PLOD1, SETD3
GO pathways analysis to identify pathways enriched in the host genes of A.
novel RNAs not previously characterised in other tissues or B. the top 10%
most abundant circRNAs in human islets are presented here. Number of
genes = number of differentially-expressed genes in each pathway
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profile reported here was also apparent (supplementary
Table S3).
A second islet circRNA profile has also been reported
[18]. This profile was based on a microarray approach,
identified 3441 islet circRNAs from a study of 3 human islet
samples (two female and one male donor). Since this is a
microarray-based profile, it will only contain circRNAs that
have been already annotated. The most abundant circRNA
in this study derived from the HIPK3 gene. We also identi-
fied a circRNA deriving from this gene in the top 75 most
abundant circRNA transcripts in our profile. This study dif-
fers from ours in that follow up work on circRNA expres-
sion in cell lines and in relation to T2D status occurred in
animal models and not in human cells and tissues.
Our data, like those reported in previous islet studies
[17, 18] suggests that many of the circRNAs we have iden-
tified are regulated independently of their linear counter-
parts (Supplementary Figure S2). In some cases, we have
identified associations between cell treatments or T2D sta-
tus with circRNAs in the absence of apparent effects on
their linear transcripts. Comparison of circRNA expres-
sion across tissues showed expression patterns of many
circRNAs were often higher in brain tissues compared to
other tissues, which is in line with existing knowledge that
circRNAs accumulate in the brain [27].
Some of our circRNAs are associated with glycaemic
traits in human islets. The expression of circCIRBP dem-
onstrates a negative association with insulin secretory
index (SI) of the donor islets, is elevated in human
EndoC-βH1 beta cells treated with palmitic acid and is
reduced in islets from donors with T2D. The parent
gene CIRBP (Cold Inducible RNA Binding Protein) has
roles in genotoxic stress response, not only from cold,
but also from other cellular stressors such as hypoxia
[28]. Elevated levels have been associated with mainten-
ance of glucose metabolism and protection from cold
exposure through effects on the AKT pathway [29]. The
elevated levels we demonstrate in the human beta cell
line EndoC-βH1 treated with palmitate may therefore
represent an acute stress response to altered lipid. The
lower levels in the islets of individuals with T2D may re-
flect lower stress tolerance in diabetic islets, and as may
the inverse correlation with SI, since we have previously
demonstrated that stressed beta cells can transdifferenti-
ate into delta cells in vitro [23].
We also identified elevated levels of both circCAMP-
SAP1 and its host gene CAMSAP1 in the islets of donors
with T2D. CAMSAP1 encodes an organisation protein
involved in microtubule dynamics and localisation [30].
The dynamics of microtubule assembly and disassembly
Fig. 2 Differential expression of circCAMSAP1, circCIRBP, circRPH3AL and circZKSCAN1 in diabetic islets. Expression levels of circular and linear
transcripts of the top 5 most abundant circRNAs in human islets are given here in relation to T2D status. Islets from non-diabetic individuals are
given in grey (n = 50), those from individuals with T2D are given in black (n = 20). Relative expression of each linear or circular RNA is given on
the Y axis, and was quantified relative to the geometric mean across all samples, since endogenous control genes alone did not provide a stable
baseline. Statistical significance in difference of expression between islets from donors with or without T2D is indicated by stars. * = < 0.05,
** = < 0.005, *** = < 0.001
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has an impact on the insulin secretion machinery; trans-
location and movement of insulin granules along micro-
tubules can influence their availability for secretion.
Failure to disassemble can impede docking. Microtubule
density is higher in the islets of diabetic mice compared
with non-diabetic littermates [31]. We also identified an
association between circCAMSAP1 expression and dia-
betes status in the peripheral blood of individuals with
T2D, although this was the inverse of that seen in islets.
CAMSAPs are active in multiple tissues, and also have
roles in white blood cells, which rely on the tubulin-
microtubule system for lymphocyte activation [32]. The
effect of T2D status on circCAMSAP1 expression in
blood may therefore reflect potential tissue-specific ac-
tivities of this circRNA. ZKSCAN1 and its circular RNA
circZKSCAN1 have been described as inhibitors of cellu-
lar proliferation and survival [33]. Both transcripts
demonstrate elevated expression in islets from donors
with T2D, which may perhaps reflect adverse effects on
beta cell survival. CircRPH3AL was also upregulated in
diabetic islets. Linear transcripts from RPH3AL are
highly expressed in β-cells and have roles in calcium-
dependent exocytosis during granule maturation and in-
sulin secretion [34].
We hypothesised that dysregulation of circRNA ex-
pression may underpin some of the GWAS association
signals for T2D. Thirteen circRNAs colocalised to the
recombination windows surrounding the 6 of the GWAS
index loci, but none of these demonstrated differential
expression by risk genotype. This suggests that the gen-
etic associations between individual genetic variants and
T2D is probably not mediated by dysregulation of islet
circRNAs.
Table 4 Association of expression of circRNAs mapping to T2D-GWAS loci and their parental transcripts with genotype in primary
non-diabetic islets
Transcript GG Gg and gg
p-value Mean SD Mean SD
rs6819243
CTBP1 0.781 −0.11 0.32 −0.04 0.34
CircCTBP1_1 0.274 −0.03 0.65 0.09 0.37
CircCTBP1_2 0.293 0.00 0.85 0.11 0.85
rs10758593
GLIS3 0.139 −0.19 0.37 0.02 0.36
CircGLIS3 0.535 0.03 0.37 0.04 0.41
rs7177055
HMG20A 0.502 −0.03 0.38 0.09 0.37
CircHMG20A 0.952 0.03 0.36 0.03 0.38
rs1111875
IDE 0.578 −0.66 0.39 −0.46 0.35
CircIDE1 0.953 −0.02 0.40 0.04 0.45
CircIDE2 0.937 −0.02 0.23 0.02 0.36
rs12427353
SPPL3 0.808 −0.01 0.48 0.05 0.43
CircSPPL3_1 0.677 −0.02 0.45 0.06 0.34
CircSPPL3_2 0.595 0.01 0.48 0.21 0.48
rs10203174
THADA 0.369 −0.02 0.61 0.22 0.50
CircTHADA1 0.672 0.05 0.40 0.10 0.42
CircTHADA2 0.282 −0.01 0.86 − 0.33 0.96
CircTHADA3 0.133 0.11 0.32 0.16 0.45
CircTHADA4 0.319 0.06 0.39 −0.24 0.46
CircTHADA5 0.651 0.14 0.59 0.27 0.40
The association between circRNA/linear transcript expression and genotype for circRNAs located to GWAS loci for T2D are given. Heterozygous samples and minor
allele homozygotes are combined into one category. SD = standard deviation. Genotypes: GG =most common allele observed. Gg = heterozygotes, gg =minor
allele heterozygotes
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Table 5 Expression of most abundantly expressed circRNAs and
their parental transcripts in EndoC-βH1 cells treated with
diabetes-related stresses
Transcript Treatment p-value Median (IQR)
CAMSAP1 Control 1.11 (0.95–1.39)
2.5 mM glucose 0.313 1.03 (0.92–1.05)
25 mM glucose 0.444 0.96 (0.95–1.17)
Control 0.92 (0.89–1.06)
1% O2 0.694 0.97 (0.73–1.04)
3% O2 0.347 0.88 (0.63–0.99)
Control 1.05 (0.95–1.08)
Palmitic acid 0.062 0.89 (0.77–0.94)
Control 0.93 (0.25–1.21)
Cytokines 0.635 0.95 (0.90–0.99)
CircCAMSAP1 Control 0.84 (0.79–1.11)
2.5 mM glucose 0.762 1.02 (0.75–1.12)
25 mM glucose 0.681 0.92 (0.78–1.29)
Control 0.98 (0.92–1.14)
1% O2 0.136 0.89 (0.76–0.93)
3% O2 0.292 0.83 (0.63–1.07)
Control 1.04 (1.02–1.23)
Palmitic acid 0.090 0.82 (0.65–1.00)
Control 0.77 (0.27–1.14)
Cytokines 0.555 0.99 (0.69–1.02)
CIRBP Control 1.06 (0.83–1.08)
2.5 mM glucose 0.080 1.38 (1.10–1.53)
25 mM glucose 0.077 1.30 (1.14–1.56)
Control 1.01 (0.99–1.09)
1% O2 0.146 0.79 (0.39–0.97)
3% O2 0.129 0.84 (0.74–1.02)
Control 0.88 (0.65–1.09)
Palmitic acid 0.907 0.91 (0.64–1.15)
Control 0.90 (0.03–1.34)
Cytokines 0.593 0.95 (0.93–1.06)
CircCIRBP Control 0.77 (0.61–1.42)
2.5 mM glucose 0.844 0.86 (0.32–1.37)
25 mM glucose 0.652 0.77 (0.72–0.94)
Control 1.10 (1.00–1.23)
1% O2 0.955 0.86 (0.56–2.00)
3% O2 0.726 0.89 (0.68–1.48)
Control 0.75 (0.72–1.04)
Palmitic acid 0.021 1.69 (1.30–1.98)
Control 1.17 (1.00–1.33)
Cytokines 0.180 0.73 (0.69–1.06)
RPH3AL Control 1.05 (0.93–1.06)
2.5 mM glucose 0.503 0.99 (0.75–1.07)
Table 5 Expression of most abundantly expressed circRNAs and
their parental transcripts in EndoC-βH1 cells treated with
diabetes-related stresses (Continued)
Transcript Treatment p-value Median (IQR)
25 mM glucose 0.441 0.93 (0.80–1.08)
Control 1.09 (1.06–1.37)
1% O2 0.357 1.55 (1.04–1.56)
3% O2 0.205 1.32 (1.28–1.81)
Control 0.95 (0.87–0.99)
Palmitic acid 0.102 0.84 (0.70–0.87)
Control 0.98 (0.02–1.01)
Cytokines 0.354 1.02 (0.91–1.12)
CircRPH3AL Control 1.00 (0.45–1.00)
2.5 mM glucose 0.941 0.85 (0.58–0.97)
25 mM glucose 0.867 0.76 (0.73–0.86)
Control 1.09 (1.06–1.37)
1% O2 0.357 1.55 (1.04–1.56)
3% O2 0.205 1.32 (1.28–1.81)
Control 1.66 (1.32–1.85)
Palmitic acid 0.022 0.97 (0.95–1.11)
Control 0.68 (0.47–0.77)
Cytokines 0.295 0.97 (0.55–1.02)
RHOBTB3 Control 1.24 (1.23–1.31)
2.5 mM glucose 0.188 1.11 (1.00–1.27)
25 mM glucose 0.117 1.20 (0.72–1.14)
Control 0.95 (0.69–1.06)
1% O2 0.949 0.97 (0.77–0.98)
3% O2 0.353 0.67 (0.65–0.93)
Control 0.80 (0.72–0.90)
Palmitic acid 0.003 1.18 (1.15–1.21)
Control 1.17 (0.29–1.35)
Cytokines 0.186 1.59 (1.22–1.72)
CircRHOBTB3 Control 0.74 (0.73–1.00)
2.5 mM glucose 0.836 0.89 (0.65–1.02)
25 mM glucose 0.351 0.77 (0.57–0.78)
Control 1.04 (0.72–1.08)
1% O2 0.182 0.78 (0.74–0.78)
3% O2 0.288 0.79 (0.77–0.86)
Control 1.16 (0.99–1.27)
Palmitic acid 0.306 1.03 (0.83–1.13)
Control 1.01 (0.95–1.08)
Cytokines 0.628 0.97 (0.89–1.06)
ZKSCAN1 Control 1.24 (1.18–1.33)
2.5 mM glucose 0.632 1.23 (1.05–1.87)
25 mM glucose 0.997 1.23 (1.16–1.36)
Control 0.93 (0.86–1.08)
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We acknowledge that at present however, our data are
largely correlative, and at present do not offer information
on causality, definitive mechanistic proof or insight into the
regulatory relationships between circRNAs and their host
genes. CircRNAs can have effects in cis by regulating the
transcription, linear splicing or translation of linear tran-
scripts from their host genes [35–40]. In our data, we ob-
serve similar responses of linear and circular transcripts in
response to challenge (CAMSAP1/circCAMSAP1, CIRBP/
circCIRBP, ZKSCAN1/circZKSCAN1). This may be a mani-
festation of effects on transcription of common pre-RNAs
from which both forms can be expressed. Other circRNAs
show dysregulated expression for the circRNA alone (cir-
cRPH3AL). This suggests that the effect of circRNA regula-
tion is post-transcriptional in these cases. CircRNAs can
also act in trans, by virtue of sponging of other non-coding
(nc) RNAs or RNA binding proteins [41–43]. In these
cases, it is impossible to deduce from our data what the
molecular targets of dysregulated islet circRNAs may be.
Conclusion
In conclusion, we present here an enriched circular RNA
profile in human pancreatic islets. Although we find no
evidence that the associations between T2D and genetic
variation are underpinned by effects on the circRNA mi-
lieu, we demonstrate that the majority of the most abun-
dant islet circRNAs display associations between their
expression and aspects of glucose homeostasis in human
donors, as well as associations with other glycaemic mea-
sures. One circRNA, circCAMSAP1, also demonstrated al-
tered expression in the peripheral blood of individuals
with T2D, and may have future utility as a biomarker.
Fig. 3 Differential expression of circZKSCAN1 in peripheral blood of T2D participants Peripheral blood circRNA levels are given here for non-
diabetic samples (labelled in mid-grey; n = 133), samples from individuals who have overt diabetes (labelled in black; n = 106) and those with
impaired glucose tolerance IGT (labelled in light grey; n = 46). Relative expression of circRNAs is given on the Y axis and was quantified relative to
the geometric mean across all samples, since endogenous control genes alone did not provide a stable baseline. Statistical significance in
difference of expression between early and late passage cells is indicated by stars. * = < 0.05, ** = < 0.005, *** = < 0.001
Table 5 Expression of most abundantly expressed circRNAs and
their parental transcripts in EndoC-βH1 cells treated with
diabetes-related stresses (Continued)
Transcript Treatment p-value Median (IQR)
1% O2 0.388 1.06 (0.94–1.12)
3% O2 0.218 0.72 (0.66–0.98)
Control 0.50 (0.39–0.55)
Palmitic acid 0.001 1.01 (0.94–1.12)
Control 1.29 (0.24–1.33)
Cytokines 0.378 1.30 (1.27–1.35)
CircZKSCAN1 Control 0.86 (0.81–1.17)
2.5 mM glucose 0.490 0.91 (0.83–1.17)
25 mM glucose 0.505 0.88 (0.83–1.28)
Control 1.11 (0.99–1.42)
1% O2 0.060 1.65 (1.41–1.79)
3% O2 0.631 1.24 (1.02–1.57)
Control 1.01 (0.81–1.45)
Palmitic acid 0.252 0.83 (0.75–0.91)
Control 1.05 (0.10–1.13)
Cytokines 0.292 1.16 (1.13–1.18)
We assessed the effect of diabetes-related cellular stresses (low/high glucose,
elevated fatty acid, hypoxia and exposure to pro-inflammatory cytokines) on
the expression of the 5 most abundant islet circRNAs in the Endo-βH1 human
beta cell line. IQR = interquartile range. Results meeting the threshold for 4
test conditions are given in bold underlined type, those presenting nominal
associations only are indicated in bold italic type
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integrity number; qRT-PCR: Quantitative reverse transcription PCR;
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